Keyphrases
Pharmacokinetics
61%
Physiologically-based Pharmacokinetic Model
41%
Pharmacokinetic Modeling
39%
Virtual Clinical Trials
38%
During Pregnancy
31%
Plasma Concentration
22%
Population Groups
21%
Blood-brain Barrier
19%
Precision Dosing
19%
Drug Interactions
15%
Drug Delivery
15%
Pediatric
14%
Rifampicin
14%
Malaria
12%
Dosing Regimen
12%
Central Nervous System
12%
Fixed-dose Combination
11%
Extensive Metabolizer
11%
Human Pharmacokinetics
10%
Nose-to-brain Delivery
10%
Pharmacokinetic Study
10%
Cytochrome P450 2D6 (CYP2D6)
10%
Phytochemicals
10%
ATP Binding Cassette Subfamily B Member 1 (ABCB1)
10%
Dose Optimization
10%
Dose Adjustment
10%
Trimester
9%
Cancer Population
9%
Antimalarial Activity
9%
Lumefantrine
9%
Clinical Trials
9%
Breast Cancer Resistance Protein
9%
Orally Disintegrating Tablet
9%
Nucleotide-binding Domain
9%
P-glycoprotein (P-gp)
9%
Poor Metabolizer
9%
Modeling Approach
9%
Liposomes
8%
Tween 20
8%
Amlodipine
8%
Curcumin
7%
Methadone
7%
Therapeutic Window
7%
Maternal-fetal
7%
CYP2C19
7%
Elastic Liposomes
7%
Efavirenz
7%
Human Brain Microvascular Endothelial Cells (HBMEC)
7%
Cardiovascular Disease
7%
Daily Dose
7%
Pharmacology, Toxicology and Pharmaceutical Science
Pharmacokinetics
100%
Clinical Trial
40%
Pharmacokinetic Modeling
38%
Drug-Drug Interaction
17%
Physiologically Based Pharmacokinetic Modelling
16%
Blood-Brain Barrier
15%
Rifampicin
14%
Liposome
14%
Tablet
12%
Bioavailability
11%
Disease
11%
Phytochemical
10%
ABCG2
9%
Benflumetol
9%
Methadone
9%
Antimalarial Agent
9%
P-Glycoprotein
9%
Malignant Neoplasm
9%
Amlodipine
8%
Polysorbate 20
8%
Effusion
7%
Therapeutic Window
7%
Efavirenz
7%
Cardiovascular Disease
7%
CYP2D6
7%
Bioequivalence
7%
CYP2B6
6%
CYP3A4
6%
Transdermal
6%
Poloxamer
6%
CYP2C19
6%
Central Nervous System Drug
6%
Clinical Pharmacokinetics
5%
Surfactant
5%
Skin Cancer
5%
Controlled Release
5%
Curcumin
5%
Drug Absorption
5%